AstraZeneca shares have been performing impressively in the recent past, with reports of them hitting an all-time high at both
212.37 USD and
190.19 USD. The stock even soared 103%, and consequently received a
rating upgrade. High purchase volume from investment firms such as Factory Mutual Insurance, Wealthcare Advisory Partners and JPMorgan Chase & Co. demonstrates strong investor confidence. AstraZeneca also started trading in the U.S., syncing its listing across London Stock Exchange, Nasdaq Stockholm and NYSE. While facing competition from pharmaceutical giants like Pfizer, AstraZeneca is appreciated as a leading
immunotherapy stock and is projected as one of Bank of America’s Top 25 Stocks for 2026. Based on its strong
cancer drug demand, the company forecasts steady growth and aspires for an $80 billion view by 2030. However, AstraZeneca shares saw a slight dip after a rating cut and pause in UK investment. The rejection of its lupus drug in injection form by the FDA also negatively impacted the stock.
AstraZeneca Stocks News Analytics from Tue, 01 Jul 2025 07:00:00 GMT to Sat, 21 Feb 2026 08:52:48 GMT -
Rating 8
- Innovation 6
- Rumor -4
